AI is changing the re-identification threat model. The life sciences industry needs to stay ahead of it with rigor, practical innovation, and defensible anonymization strategies.
A clinical data package that appeared appropriately anonymized in the past may face a different risk environment today. AI tools can help motivated actors connect weak signals across registries, publications, adverse event narratives, clinical trial records, and other public sources more quickly than before. That does not mean anonymization is broken. It means anonymization strategies need to keep evolving.
AI is not making clinical data anonymization obsolete.
It is making responsible anonymization more important than ever.
For life sciences organizations, the core challenge has always been the same: protect participant privacy while preserving enough data utility to support meaningful research, regulatory transparency, and public trust.
That balance is difficult, but it is not new. Clinical data anonymization has always required discipline, judgment, and evidence-based decision-making. The industry already has strong foundations, including statistical privacy frameworks, quantitative risk assessment methods, and regulatory expectations from agencies such as EMA and Health Canada.
What is new is the environment around that work.
Large language models and other AI technologies are changing what can be inferred from publicly available information. They can synthesize signals across clinical trial registries, medical literature, adverse event databases, publications, and other external sources at a speed and scale that was not previously practical. The concern is not that AI magically identifies participants from anonymized data. The concern is that AI may reduce the time, expertise, and effort required to perform linkage, inference, and contextual narrowing across multiple sources.
That does not mean anonymization is broken.
It means the bar is rising.
And the organizations responsible for protecting participant privacy need to rise with it.
At Real Life Sciences, this is exactly the type of challenge we believe the industry should take seriously: not with fear, not with overstatement, but with practical, disciplined innovation.
The Industry Was Already Told to Expect This
One reason this topic matters is that it is not disconnected from existing regulatory expectations.
EMA guidance has long recognized that anonymization is not a one-time exercise frozen in time. It calls on data controllers to continuously follow developments in re-identification techniques and, when necessary, reassess the risk of re-identification. The guidance also emphasizes the need to consider realistic future developments in technologies that could allow identification. In other words, the guidance already anticipated that the threat model would evolve.
This is important because EMA’s position does not treat anonymization as a one-time technical exercise. It expects organizations to monitor advances in re-identification techniques and reassess risk when the external environment changes.
That is the key point.
The life sciences industry was never supposed to treat anonymization as static. The expectation has always been that risk assessment should evolve as data sources, linkage techniques, and analytical capabilities evolve.
Traditional anonymization approaches remain essential. Methods such as k-anonymity and l-diversity remain important in quantitative risk assessment, while differential privacy is an important privacy concept that may be relevant in specific data-sharing scenarios. Together, these approaches reflect the statistical rigor that remains central to responsible clinical data sharing.
But a strong foundation does not mean the work stands still.
Re-identification techniques evolve. Public data sources expand. Analytical tools become more capable.
That evolution was always expected. The form it has taken is AI, and the industry needs to respond accordingly.
What AI Actually Changes
Traditional re-identification risk is often evaluated through known quasi-identifiers and available external datasets. In practical terms, the concern is whether an individual could be matched or inferred based on combinations of information such as age, sex, geography, dates, diagnosis, treatment history, rare adverse events, or other distinguishing characteristics.
Large language models introduce a different kind of pressure.
They do not necessarily need to identify someone through a single direct match. They can help synthesize information, connect patterns, and narrow possibilities across many sources. The risk is not only direct identification. It is inference, linkage, and contextual narrowing.
That distinction matters.
Recent research from Cornell Tech and Weill Cornell Medicine made this concern more concrete. In a study using an LLM-based adversarial approach, researchers tested whether patients could be re-identified from redacted clinical notes. Even after strong de-identification methods had been applied, the study reported that the approach correctly re-identified patients in 9% of the notes tested.
This finding should be interpreted carefully. The study focused on redacted clinical notes, not regulatory clinical trial disclosure packages. It should therefore be viewed as a signal about evolving adversarial capability rather than a direct benchmark for CSR anonymization or Policy 0070 disclosure.
That finding is not a reason to declare anonymization ineffective.
It is a reason to take the evolving threat model seriously.
The research shows that the risk is not limited to obvious identifiers. AI can surface connections from context, phrasing, rare clinical details, and external information that traditional workflows may not fully account for.
This is also where the emerging academic discussion around pseudo-reidentification becomes relevant. Recent academic work uses the term to describe scenarios where an AI system may not definitively identify a participant, but can narrow the field enough to create meaningful privacy concern. In clinical research, that distinction matters because privacy harm does not always begin only when a name is produced.
That is the shift.
AI does not just increase the speed of old re-identification methods. It changes what a motivated actor may be able to infer.
This is where product innovation becomes important. The next generation of anonymization platforms should not simply automate redaction or calculate static risk. They should help teams identify higher-risk attribute combinations, understand why those combinations matter, select appropriate anonymization strategies, preserve data utility, and document decisions in a repeatable way.
This Is Not a Crisis. It Is a Leadership Moment.
When a new threat model emerges, there are two easy mistakes to make.
One is panic.
The other is complacency.
The better response is leadership.
For life sciences organizations, leadership means continuing to strengthen how anonymization workflows identify risk, guide decision-making, preserve data utility, and document the rationale behind each choice.
It may be tempting to respond to AI-driven re-identification risk by adding a simple “AI risk score” to a dashboard and calling it progress. But responsible innovation has to go deeper than that.
A score that cannot be validated, explained, or defended may create the appearance of control without providing meaningful confidence.
The stronger path is to build on the rigor already recognized by regulators and trusted by practitioners, then apply that rigor to the realities of an AI-enabled world.
That means focusing on three practical areas.
-
Better Visibility into Risk
Organizations need clearer insight into which data attributes may create higher exposure in an AI-enabled environment.
Rare adverse events, narrow date ranges, small patient populations, unique treatment paths, geographic combinations, and unusual clinical narratives may all require closer review. These details may not identify a participant on their own, but in combination with external information, they can increase the risk of inference.
The opportunity is to make that visibility more systematic.
Teams should not have to rely only on individual reviewer judgment or manual interpretation. They need workflows that help surface where risk may exist, explain why it matters, and support more confident anonymization decisions.
This is where product design matters.
The best tools should not simply ask users to make difficult privacy decisions in isolation. They should help users understand the risk, apply the right strategy, and document the rationale in a way that can stand up to scrutiny.
Product opportunity: surface risk earlier, not after the anonymization strategy has already been selected.
-
Smarter Anonymization Strategies
Existing anonymization methods remain highly valuable. The question is how to help teams apply them more intelligently as the threat model evolves.
That may mean more conservative thresholds in certain scenarios. It may mean closer attention to attribute combinations. It may mean stronger documentation of risk decisions or more guided workflows that help users understand when additional protection may be warranted.
The goal is not to replace human expertise.
The goal is to support it.
Clinical data anonymization requires judgment. AI-aware privacy strategy should make that judgment more informed, more consistent, and more defensible.
That is an important distinction. The answer to AI-driven risk is not simply more AI. The answer is better decision support, stronger workflows, clearer evidence, and tools that help experts apply anonymization strategies with confidence.
Product opportunity: guide users toward strategy choices based on the nature of the risk, the data context, and the utility impact.
-
Continuous Validation
As AI capabilities continue to advance, anonymization practices will need to be evaluated against emerging inference and linkage techniques.
That does not mean every organization needs to invent a new methodology overnight. It means the industry should move toward more empirical, evidence-based validation of how anonymized data may perform in a changing risk environment.
This is how the industry can test anonymization strategies against the next generation of adversarial methods.
Not by reacting after risk emerges.
Not by making broad claims that cannot be substantiated.
But by continuously testing assumptions, monitoring the science, and improving the way anonymization strategies are designed, configured, and documented.
In a regulated environment, innovation is only valuable if it can be trusted.
Product opportunity: support repeatable validation, evidence capture, and reassessment as public data sources, linkage methods, and AI capabilities evolve.
What This Means for Product Innovation
AI-aware anonymization does not mean replacing expert judgment with a black-box score. It means giving experts better tools to identify risk, select appropriate strategies, preserve data utility, and document decisions clearly.
Product innovation should focus on three areas: earlier identification of high-risk attributes and attribute combinations, guided strategy selection that balances privacy protection and data utility, and stronger documentation and validation so decisions can be explained, reviewed, and defended.
This is especially important in clinical disclosure, where sponsors must protect participant privacy while still supporting transparency, regulatory expectations, and responsible research use.
Why Structure Matters
AI-driven re-identification risk reinforces an important point: responsible anonymization cannot depend on manual judgment alone.
Sponsors need structured processes that help teams assess risk, apply anonymization strategies, preserve data utility, and document decisions clearly. That structure matters because clinical disclosure is not simply about removing information. It is about making defensible privacy decisions in a highly regulated environment.
The goal is to protect participant privacy while preserving the value of clinical data for research, review, and public trust.
This is the balance the RLS Protect Platform was built to support. Within the platform, RLS Protect Risk helps sponsors move from judgment-heavy, manual anonymization decisions to structured, evidence-based workflows that support risk assessment, strategy selection, residual risk evaluation, utility preservation, and defensible documentation within a repeatable clinical disclosure workflow.
As AI changes the privacy landscape, that balance becomes even more important. The future of anonymization will not be defined by a single model, metric, or feature. It will be defined by how well organizations combine statistical rigor, regulatory understanding, domain expertise, and AI-aware privacy thinking into practical workflows that sponsors can use with confidence.
That is where Real Life Sciences is focused: helping sponsors make better, more defensible decisions as the risk environment changes.
The Opportunity Ahead
AI-related governance, safety, privacy, and misuse concerns are growing across industries. Stanford’s 2025 AI Index Report found that reported AI-related incidents reached a record high in 2024, increasing 56.4% over the prior year.
For life sciences organizations, this reinforces an important point: AI governance, data privacy, and anonymization strategy can no longer be treated as separate conversations.
They are connected.
This matters now because clinical transparency expectations are expanding at the same time AI capabilities are accelerating. Sponsors are being asked to share more, explain more, and defend more, while the tools available to infer sensitive information are becoming more powerful.
The organizations that engage seriously with these questions now will be better prepared as expectations evolve. They will be better positioned for regulatory conversations, data-sharing negotiations, internal governance reviews, and sponsor commitments around responsible transparency.
Most importantly, they will be better equipped to protect patient trust while continuing to support the responsible sharing of clinical information.
This is not about suggesting today’s anonymization practices are obsolete.
It is about recognizing that expectations are moving forward.
And the organizations that move forward first will help shape what good looks like.
Staying Ahead
AI-driven re-identification is an emerging area of risk, and industry best practices will continue to evolve. Our view is that the right response is not fear or overstatement.
It is disciplined innovation.
That means monitoring the science.
Strengthening anonymization strategies.
Supporting smarter configuration decisions.
Validating assumptions.
Preserving data utility.
And helping sponsors prepare for the next generation of privacy expectations.
At Real Life Sciences, we believe this is where responsible product innovation matters most. This is an area we are actively focused on because the future of clinical disclosure will require more than static workflows. It will require platforms, processes, and partners that can adapt as the risk landscape changes.
The industry needs practical, defensible, forward-looking approaches that acknowledge the evolving risk landscape without overstating it, helping organizations stay ahead of privacy risks while continuing to meet clinical disclosure and transparency obligations.
AI is changing the re-identification threat model. The future of clinical transparency will belong to organizations that can share data responsibly, defend their privacy decisions, and adapt as the risk landscape evolves.
That is the future RLS is building toward: clinical transparency workflows that are structured, evidence-based, AI-aware, and defensible.
Jon Nolan is Director of Product Management at Medispend. The Medispend Protect Platform supports clinical disclosure and transparency workflows designed to help sponsors protect participant privacy, preserve data utility, and produce defensible outputs for responsible research transparency.
Medispend AI Innovation Lab
The Medispend AI Innovation Lab is a collaborative program that brings together customers, industry experts, and Medispend leaders to explore emerging AI capabilities, validate real-world use cases, and help shape the future of AI in life sciences. Through ongoing customer engagement and innovation initiatives, the Lab helps ensure that AI investments remain practical, governed, and aligned with the evolving needs of regulated organizations.
Sources and Further Reading
The following sources informed the discussion of AI-driven re-identification risk, regulatory expectations, and emerging privacy challenges in clinical data sharing.
- European Medicines Agency, External Guidance on the Implementation of Policy 0070
Provides the regulatory foundation for clinical data anonymization expectations, including the need to monitor evolving re-identification techniques and reassess risk where necessary. - Morris et al., DIRI: Adversarial Patient Reidentification with Large Language Models for Evaluating Clinical Text Anonymization
Provides an example of an LLM-based adversarial approach to re-identification in redacted clinical notes. Relevant as a signal of evolving adversarial capability, not as a direct benchmark for regulatory clinical trial disclosure packages. - Hallaj et al., Open Data Sharing in Clinical Research and Participants Privacy: Challenges and Opportunities in the Era of Artificial Intelligence
Discusses privacy risks in open clinical data sharing in the age of AI, including the emerging concept of pseudo-reidentification. - Stanford Institute for Human-Centered Artificial Intelligence, 2025 AI Index Report
Provides broader context on the rise in reported AI-related incidents and growing AI governance, safety, privacy, and misuse concerns.
Jon Nolan
Director of Product Management
